Search - tctmd.com

Displaying 1 - 20 of 138

Sort: Relevancy | Date

News Conference News TCT 2016

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Todd Neale

November 02, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Hitinder S. Gurm

November 01, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Gennaro Giustino

November 01, 2016

News Industry News TCT 2016

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Presentation TCT 2016

Strategy Trials: ISCHEMIA/EXCEL/FREEDOM: Strengths and Weaknesses

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, David J. Cohen

November 01, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

Presentation TCT 2016

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, David J. Cohen

October 30, 2016

News Opinion Conversations in Cardiology

Conversations in Cardiology: In the United States, Should TAVR Be Offered to a Low-Risk Patient?

July 11, 2016

News Conference News TVT 2016

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

Michael O'Riordan

June 20, 2016

Presentation TVT 2016

New TAVR Risk Models (eg, From TVT and FRANCE 2 Registries): Development, Clinical Validation, Current Use, and Future Directions

Presenter: David J. Cohen

June 17, 2016

Presentation TVT 2016

Identifying the Futile AS Patient: When Are Extreme Comorbidities Too Much for TAVR?

Presenter: David J. Cohen

June 17, 2016

Presentation TVT 2016

The Reemergence of Transcarotid TAVR as a Worthwhile Alternative

Presenter: David J. Cohen

June 16, 2016

Presentation Fellows 2016

Antithrombin Pharmacology for the Interventionalist

Presenter: Jeffrey W. Moses, David J. Cohen

April 16, 2016

Presentation Fellows 2016

Essentials of Clinical Trial Design: Statistics 101 for the Interventionalist

Presenter: Gary S. Mintz, David J. Cohen

April 16, 2016

News Daily News

AVB Absorb: Seguridad, Eficacia y Trombosis del Stent a Estudio en 2 Nuevos Análisis

Michael O'Riordan

March 30, 2016

News Daily News

Absorb BVS: Safety, Efficacy, and Stent Thrombosis Tackled in Two New Analyses

Michael O'Riordan

March 30, 2016

News Daily News

Absorb BVS：两项新研究解决了安全性、有效性和支架血栓问题

Michael O'Riordan

March 30, 2016

News Daily News

Newer-Generation DES With Abbreviated DAPT Bests BMS in Patients at High Risk for Bleeding

L.A. McKeown

March 08, 2016

Advertisement

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Strategy Trials: ISCHEMIA/EXCEL/FREEDOM: Strengths and Weaknesses

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Conversations in Cardiology: In the United States, Should TAVR Be Offered to a Low-Risk Patient?

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

New TAVR Risk Models (eg, From TVT and FRANCE 2 Registries): Development, Clinical Validation, Current Use, and Future Directions

Identifying the Futile AS Patient: When Are Extreme Comorbidities Too Much for TAVR?

The Reemergence of Transcarotid TAVR as a Worthwhile Alternative

Antithrombin Pharmacology for the Interventionalist

Essentials of Clinical Trial Design: Statistics 101 for the Interventionalist

AVB Absorb: Seguridad, Eficacia y Trombosis del Stent a Estudio en 2 Nuevos Análisis

Absorb BVS: Safety, Efficacy, and Stent Thrombosis Tackled in Two New Analyses

Absorb BVS：两项新研究解决了安全性、有效性和支架血栓问题

Newer-Generation DES With Abbreviated DAPT Bests BMS in Patients at High Risk for Bleeding

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content